OrthoPediatrics (KIDS) Q3 2026 earnings review
OrthoPediatrics generates cash as sales jump, but GAAP losses continue
OrthoPediatrics grew faster across both of its surgical divisions and generated positive free cash flow ahead of the fourth quarter. Revenue at the maker of children's orthopedic implants and braces rose 19% to $73 million as scoliosis sales rebounded from a second-quarter drop. Chief executive David Bailey raised the full-year sales outlook, though by our math the plan points to growth slowing to 12% in the fourth quarter.
| Revenue | $72.7M +18.6% from a year ago |
|---|---|
| Free cash flow | $1.6M -$3.4M a year ago |
| Adjusted EBITDA, excluding one-offs | $6.9M +12.1% from a year ago |
| Full-year revenue outlook | Raised $4.5M middle of the range: 14.9% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because third-quarter free cash flow of $1.6 million took the pressure off the full-year breakeven target, leaving $6.6 million to generate in the fourth quarter by our math. One caution: higher sales commissions held back cash profit, so the company did not raise its full-year cash earnings plan alongside revenue, and standard net losses continue.
The question now is whether cutting back on hospital instrument sets is starving future product launches to hit this year's cash target. If the cutback is harmless, new implants will keep revenue growing near 20%; if it starves launches, growth will fade once the current hospital sets are full. Fourth-quarter set spending and the 2027 outlook will tell.
🐂 Bull Case
Free Cash Flow Turned Positive Ahead of Q4
OrthoPediatrics makes surgical implants and braces for children, and chief executive David Bailey wants it to fund its own growth. He reiterated the goal of "achieving breakeven or better free cash flow on an annual basis in 2026 and beyond". Critics doubted this plan after first-half cash usage of $8.2 million left a steep climb for the second half.
The company generated $1.6 million of free cash flow in the third quarter, reversing $3.4 million of cash burn a year ago. OrthoPediatrics said "Increased adjusted EBITDA, lower sets deployed and improved working capital metrics all contributed to the year-over-year improvement".
This positive quarter makes the full-year breakeven target much easier to reach. By our math, nine-month free cash flow of negative $6.6 million leaves $6.6 million to generate in the fourth quarter. That is well below the $9.8 million the business produced in the fourth quarter of last year.
What to watch: fourth-quarter operating cash flow and property purchases in the full-year report. Delivering at least $6.6 million of free cash flow would complete the first self-funded year in the company's history.
New Products Lifted Both Implant Divisions
"Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency," Bailey said. OrthoPediatrics is launching new bone-plating systems, scoliosis implants and custom braces from its OrthoPediatrics Specialty Bracing (OPSB) clinics.
Total revenue rose 18.6% to a record $72.7 million, beating the $68.5 million level management pointed to last quarter by our math. The Indiana-based group launched its 3P Hip plating system and PediHip brace in full, began limited launches for three other devices, and raised its full-year sales outlook by $4.5 million at the middle of the range.
- Trauma and deformity sales: $52.6 million, up 19.2% from a year ago on 3P Hip, Cannulated Screws and OPSB braces
- Scoliosis sales: $19.2 million, up 17.9% on VerteGlide and Response spine systems after falling 8.9% last quarter
- Implied fourth-quarter revenue growth: 12.0% from a year ago at the middle of the new outlook, by our math
The rebound in scoliosis shows that new spine implants are offsetting sluggish sales of 7D surgical navigation machines. Because the third quarter beat outpaced the $4.5 million full-year raise, the new plan still leaves a cautious fourth-quarter bar.
What to watch: fourth-quarter scoliosis growth against a year-ago period that included 7D machine sales. Double-digit growth would show that VerteGlide implant demand can carry the spine division on its own.
International Sales Grow on Procedure Volume
OrthoPediatrics sells implants in over 75 countries outside the United States. In the past, international growth often relied on bulk sales of surgical instrument sets to stocking distributors in Latin America, which carry low profit margins and created collection delays.
International revenue rose 17.9% from a year ago to $14.8 million, while domestic revenue grew 18.8% to $57.9 million. Overseas growth was "primarily driven by increased procedure volumes", the company said, and company-wide gross margin held steady at 74.3%, up 0.4 percentage points from a year ago by our math.
Growing through hospital surgeries rather than distributor stocking orders keeps profit margins above 74% and avoids tying up cash in unpaid bills. It also shows that recent European Union medical device approvals are winning regular hospital business.
What to watch: international revenue growth and gross margin in the fourth quarter. Holding gross margin near 74% while international sales grow at a mid-teens rate would confirm that overseas growth no longer depends on low-margin bulk shipments.
🐻 Bear Case
GAAP Losses Persist as Debt and Shares Rise
Bailey highlighted improved profitability and record cash earnings, which exclude stock awards, acquisition charges and interest. Beneath those figures, OrthoPediatrics has never earned an operating profit under standard accounting rules, and it continues to issue stock and pay more interest on its debt.
The pediatric device maker reported a third-quarter net loss of $5.9 million, bringing its nine-month net loss to $23.8 million. During the quarter, it wrote down the value of its ApiFix and MedTech brand names after an annual review showed their value fell below what the balance sheet carried.
- Net interest expense: $2.6 million, up 43.6% from $1.8 million a year ago
- Stock-based compensation: $4.4 million in the quarter and $12.6 million over nine months
- Trademark write-down: $0.6 million, marking the fifth straight year of brand impairments
- Diluted share count: 24.15 million, up 2.5% from a year ago after issuing $4.1 million of stock for deals in nine months
Excluding one-offs, diluted loss per share barely improved to $0.23 from $0.24 a year ago, because higher interest bills eat up operating gains. Paying for acquisitions and employee pay with stock also dilutes existing owners every quarter.
What to watch: net interest expense and share count in the fourth quarter. Until operating profit exceeds the $2.6 million quarterly interest bill, standard net income will stay negative.
Sales Commissions Held Back Cash Profit
As OrthoPediatrics expands its specialty bracing clinics and sells more implants, it relies on sales representatives and clinic staff to handle the volume. General and administrative expenses — overhead and clinic staff costs — fell by 3.5 percentage points of revenue to 44.1% by our math, even after hiring "additional personnel supporting clinic expansions and small-scale acquisitions".
However, sales and marketing expenses jumped 23.8% from a year ago to $23.1 million, rising by 1.3 percentage points of revenue to 31.8% on "increased sales commission expenses and an overall increase in volume of units sold", OrthoPediatrics said. Because commissions rose faster than sales, EBITDA excluding one-offs grew 12.1% to $6.9 million, lagging the 18.6% revenue gain.
That is why management left its full-year EBITDA excluding one-offs outlook unchanged at about $25.0 million despite raising the revenue plan by $4.5 million. Higher sales were offset by the commissions paid to bring them in.
What to watch: fourth-quarter EBITDA excluding one-offs, which must reach $9.1 million by our math to hit the $25.0 million full-year plan. Missing that figure would show that sales commissions are eating into operating leverage.
Risks this quarter didn't answer
Five standing concerns around capital rationing, delayed devices and accounting adjustments got no new numbers in the earnings release, as those details usually appear on the conference call or in the quarterly filing.
- Instrument set deployment in Q3: the release noted "lower sets deployed" helped cash flow and kept the $10.0 million full-year target, but did not state the quarterly dollar figure (total capital expenditures were $2.9 million).
- VerAxis and eLLi timelines: no update on FDA clearance for the VerAxis spine system (already delayed twice to early 2027) or first patient surgeries for the eLLi lengthening implant (targeted for late 2026).
- 7D surgical navigation units: no disclosure on whether any 7D machines sold in Q3 or how the company will meet $2.2 million of minimum purchase commitments through 2027.
- Brazil distributor collections: no update on withheld stocking orders or customer receivable balances in Latin America.
- Prior-period reimbursement adjustments: the release did not size the insurance rate true-ups from earlier periods that were flagged in the second-quarter filing.
👓 Other Themes
A Weaker Euro Created Foreign Exchange Losses
OrthoPediatrics sells implants across Europe and holds balances in foreign currencies. During the third quarter, the Euro fell in value against the U.S. dollar, whereas it had gained value in the same quarter of 2025. That swing created foreign exchange losses inside other expenses, OrthoPediatrics said, though a $0.8 million non-cash gain from revaluing acquisition payouts kept total other expense down at $1.8 million.
💲 Other KPIs
Inventory growth slowed to 10.1% from a year ago, well below the 18.6% rise in revenue. OrthoPediatrics holds surgical implants and instruments on hospital shelves as consignment inventory. Building stock more slowly tied up $4.9 million of operating cash over the first nine months, down from $7.9 million in the same period last year.
Uncollected customer bills rose 16.1% from a year ago by our math, growing slightly slower than the 18.6% sales increase, and dipped from $61.0 million at the end of the second quarter. Slower growth in unpaid bills plus a $5.3 million rise in accounts payable helped operating cash flow turn positive.
Total cash, restricted cash and short-term marketable securities fell by $3.0 million from the second quarter and by $18.0 million since the start of the year. Although third-quarter free cash flow was positive $1.6 million, the medical device group spent $11.7 million over nine months on clinic acquisitions, private company investments and acquisition debt payments.
🔮 Guidance
Raised. The middle of the range moved up $4.5 million to $271.5 million, or 14.9% growth for the year. By our math, that leaves $69.0 million for the fourth quarter, or 12.0% growth from a year ago against 18.6% in the third quarter. It is the third raise this year, and each was larger than the last: +$1.0M, +$2.0M, +$4.5M.
Unchanged. The plan still calls for about $25.0 million of EBITDA excluding one-offs, up 69.4% from $14.8 million in 2025. By our math, nine-month earnings of $15.9 million leave $9.1 million for the fourth quarter, almost double the $4.8 million earned a year ago and equal to a 13.2% margin on implied fourth-quarter sales.
Unchanged. Management still expects at least breakeven free cash flow for the full year, compared with $16.0 million of cash burn in 2025. By our math, after burning $6.6 million over the first nine months, the fourth quarter must generate at least $6.6 million of free cash flow, compared with $9.8 million in the fourth quarter of last year.
Unchanged. OrthoPediatrics still plans to spend about $10.0 million placing consigned surgical instrument sets in hospitals this year, down from $15.0 million in 2025 and $21.0 million in 2024. Total property and equipment purchases were $2.9 million in the third quarter and $8.7 million over the first nine months.
❓ Key Questions
How much did OrthoPediatrics spend deploying instrument sets in Q3?
Management previously said about $5 million of the $10 million full-year set budget remained for the second half, with a large batch shipping in July. Yet the release cited lower set deployments as a reason third-quarter cash flow improved.
Why didn't the $4.5 million revenue raise lift EBITDA?
OrthoPediatrics raised its full-year sales outlook by $4.5 million at the middle of the range while holding its EBITDA excluding one-offs plan at $25.0 million. Investors need to know if higher sales commissions or lower-margin fourth-quarter sales absorbed the extra revenue.
What are the standalone sales and margins of OPSB clinics?
Management credits the specialty bracing division for driving domestic growth every quarter and expanding into new territories, but it still combines bracing revenue with surgical implants inside the trauma and deformity segment.
Are eLLi and VerAxis still on track for first surgeries?
The company previously targeted late 2026 for the first patient procedures using its eLLi lengthening implant and early 2027 for its VerAxis spine system. The earnings release gave no regulatory or clinical update on either device.